COMPAR-EU aims to identify, compare, and rank the most effective and cost-effective self-management interventions (SMIs) for adults in Europe within four high-priority chronic conditions: type 2 diabetes, obesity, chronic obstructive pulmonary disease, and heart failure. This project addresses an important gap in current knowledge applying network meta-analysis, an extension of meta-analysis methodology that allows multiple (rather than pairwise) comparisons of intervention effectiveness, to randomised controlled trials (RCTs) that meet the study inclusion criteria. This centralised analysis of an estimated 4000 RCTs will substantially help to overcome current problems associated with the dispersion and duplication of evidence. The work will be based on a validated taxonomy of SMIs and will prioritise outcomes from the patients’ perspective. In addition, a cost-effectiveness of the most effective SMIs will be estimated to provide insights into the economic consequences of adopting SMIs for societies, healthcare budgets, and patients. Contextual factors associated with successful interventions will also be studied. Drawing on our results, we will develop and pilot decision-making tools to facilitate access to evidence-based information on the most effective SMIs to key users through a user-friendly interactive platform. A multiprong strategy for exploitation of the research findings will lead to clear business cases for implementing it in different contexts within the heterogeneous EU health system. The end goal of the project is to have an impact in supporting policy-makers, guideline developers, researchers, industry, professionals and patients to make informed decisions on the identification and implementation of the most suitable SMIs, therefore contributing to the diffusion of the knowledge, healthcare sustainability and equity and promoting EU competitiveness in a globally emerging market.

Due to population ageing and advances in medical science, people with chronic diseases –including advanced severe life-threatening chronic diseases- live longer. Challenges are how to sustain quality independent living for the patient; support caregivers facing an increasing burden; create sustainable healthcare and social care systems with limited resources. ADLIFE aims to provide a solution for the integration of therapies and approaches targeting early detection and assessment of deterioration, advanced and well-coordinated care planning and integrated supportive care to enhance quality of life, reduce suffering and accelerate recovery for these patients and their families. It will deploy developed and validated personalised digital solutions for integrated supportive care based on H2020 projects C3-Cloud and Power2DM, previously tested in two health systems. The ADLIFE Toolbox solutions include: a Personalised Care Plan Management Platform, Clinical Decision Support Services; Interoperability Solutions and Patient Empowerment Platform with Just-In Time Adaptive Intervention Delivery Engine. The ADLIFE system will be deployed through large-scale pilots in 7 countries and Health Systems, involve 577 healthcare professionals from 75 hospitals, clinics and primary care services. It will prove that intelligent, collaborative digital solutions can enable care teams, patients and caregivers to improve or better maintain health in patients with advanced chronic disease (over 200,000 in the participating regions). It will test its effectiveness in 882 patients and 1243 caregivers. ADLIFE will demonstrate significant outcomes-based efficiency gains in health and care delivery enhancing seamless care coordination, avoiding gaps and overlaps in care. The ADLIFE ICT Toolbox and the evidence behind this digitally-enabled approach from the 7 reference sites will be strongly disseminated to multiple stakeholders and decision makers in Europe both online and in-person actions

There are three main reasons for an immediate innovation action to apply big data technologies in Healthcare. Firstly, a Healthy nation is a Wealthy nation! An improvement in health leads to economic growth through long-term gains in human and physical capital, which ultimately raises productivity and per capita GDP. Secondly, Healthcare is one of the most expensive sectors, which accounts for 10% of the EU’s GDP continuously becoming more expensive. Thirdly, as healthcare is traditionally very conservative with adopting ICT, while big healthcare data is becoming available, the expected impact of applying big data technologies in Healthcare is enormous. BigMedilytics will transform Europe’s Healthcare sector by using state-of-the-art Big Data technologies to achieve breakthrough productivity in the sector by reducing cost, improving patient outcomes and delivering better access to healthcare facilities simultaneously, covering the entire Healthcare Continuum – from Prevention to Diagnosis, Treatment and Home Care throughout Europe. BigMedilytics produces: • A Big Data Healthcare Analytics Blueprint (defining platforms and components), which enables data integration and innovation spanning all the key players across the Healthcare Data Value Chains • Instantiations of the Blueprint which implement BigMedilytics concepts across 12 large-scale pilots accounting for an estimated 86% of deaths and 77% of the disease burden in Europe • The Best “Big Data technology and Healthcare policy” Practices related to big data technologies, new business models and European and national healthcare data policies and regulations. BigMedilytics will maximize the impact by using its Big Data Healthcare Analytics Blueprint and the Best Practices to scale-up the concepts demonstrated in the 12 pilots, to the whole Healthcare sector in Europe. It will use health records of more than 11 million patients across 8 countries and data from other sectors such as insurance and public sector.

Adverse events in health care are suffered by between 8% and 12% of patients admitted to hospitals in the EU and are accountable for around EUR 21 billion in direct costs. Surgical adverse events are one of the most common types reported. The SAFEST project aims at improving and harmonising perioperative patient safety by establishing widely supported perioperative patient-centred EU standardised practices to address this challenge. SAFEST goes beyond state of the art in surgical patient safety by addressing the whole perioperative patient?s pathway (beyond the hospital care), thus ensuring the continuum of care. Patients will participate as co-equal partners throughout the project. Their engagement will start with the broad European consensus, jointly with other key stakeholders, to design the SAFEST standardised practices for perioperative care. The SAFEST standardised practices will be implemented in 10 hospitals from 5 EU countries through a Perioperative Quality Improvement Learning Collaborative (PQILC). Our evaluation of the implementation, both from a process and a results perspective, will allow assessing the impact of the implementation of standardised practices on the improvement of clinical outcomes and to identify contextual facilitators and barriers at micro, meso and macro levels, providing new evidence to translate standardised, evidence-based guidelines to clinical practice. The uptake of the SAFEST standardised practices will be taken a step further by inviting 100 hospitals across EU-27, associated countries and beyond, to self-evaluate and create an international benchmarking assessment. Furthermore, we will ensure that SAFEST makes an impact beyond its lifespan, with ambitious dissemination and exploitation plans that include launching an open-access benchmarking platform for European hospitals and constituting an international network on perioperative patient care.

ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise iNnovative health technologies) addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. ASCERTAIN aims to enhance current methods of (value-based) pricing, cost-effectiveness modeling, threshold-setting, reimbursement, and payment, to set affordable prices, and to facilitate a cyclic assessment of broader societal benefits including costs and risks. It seeks to find a sustainable balance between access to affordable technologies, the need to stimulate innovation and entrepreneurship, and the need to consider the environmental impact of innovations. Guided by a conceptual framework integrating pricing, health technology assessment and reimbursement/payment, ASCERTAIN will develop open-access, easy to use, policy-supporting tools including (i) pricing models, (ii) value assessment models, and (iii) reimbursement models, which will be adaptable to country-specific conditions. These tools will improve transparency and accountability of decision-making, reduce uncertainty for all stakeholders, reward innovation in areas of high unmet need, accelerate access for patients, and support long-term planning in a sustainable way. Further, these tools will be developed, tested, and validated for three use cases, including precision cancer medicine, cell- and gene therapy, and medical devices (class IIb and III) or in vitro diagnostic (IVD) class D. The multinational, multidisciplinary ASCERTAIN consortium is complemented by an international advisory board consisting of key stakeholders, with whom the policy-supporting tools will be co-created. All tools will be hosted on a cloud-based, publicly accessible, user-friendly platform following open science principles.